List view / Grid view
22 July 2016 | By Niamh Louise Marriott, Digital Content Producer
UCB and Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for romosozumab, an investigational, monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture...
4 July 2016 | By Victoria White, Digital Content Producer
The EC has approved a variation to the marketing authorisation for Amgen’s Kyprolis (carfilzomib) to include use in combination with dexamethasone alone...
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS.
20 June 2016 | By Victoria White, Digital Content Producer
Santos will be responsible for Amgen's Operations organisation, including manufacturing, process development, quality, engineering and global supply chain...
13 June 2016 | By Victoria White, Digital Content Producer
A post-hoc analysis of the Phase III ASPIRE study highlighted the benefit of continued treatment with Kyprolis, lenalidomide and dexamethasone (KRd)...
10 June 2016 | By Victoria White, Digital Content Producer
Amgen's Blincyto (blinatumomab) demonstrated an almost two-times increase in median overall survival compared to standard of care...
9 June 2016 | By Victoria White, Digital Content Producer
Novartis has announced positive first results from a Phase II investigating the efficacy and safety of AMG 334 (erenumab) in chronic migraine prevention...
27 May 2016 | By Victoria White, Digital Content Producer
The CHMP has adopted a positive opinion to extend the indication for Kyprolis to include treatment in combination with dexamethasone in multiple myeloma...
6 May 2016 | By Victoria White, Digital Content Producer
Alirocumab and evolocumab are recommended for adults with primary hypercholesterolaemia or mixed dyslipidaemia...
21 April 2016 | By Victoria White, Digital Content Producer
A Phase III study shows that 52 percent of Nplate patients achieved a durable platelet response, compared with 10 percent of placebo-treated patients...
21 March 2016 | By Victoria White
The study demonstrated a statistically significant increase in bone mineral density at the lumbar spine in men with osteoporosis treated with romosozumab...
17 March 2016 | By Victoria White
A jury has delivered a verdict in Amgen's favour in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to PCSK9...
16 March 2016 | By Victoria White
NICE says there is not enough evidence to be able to say whether talimogene laherparepvec is as effective as other drugs used to treat advanced melanoma...
2 March 2016 | By Victoria White
The sBLA includes new data supporting the treatment of paediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)...
23 February 2016 | By Victoria White
The Phase III FRAME study evaluated UCB and Amgen's romosozumab in postmenopausal women with osteoporosis...
